Randomized Multicenter, Phase III Trial Evaluating the Safety of 2 Schedules of Cabazitaxel (Bi-weekly Versus Tri-weekly) Plus Prednisone in Elderly Men (≥ 65years) With mCRPC Previously Treated With a Docetaxel-containing Regimen
Latest Information Update: 14 Dec 2023
At a glance
- Drugs Cabazitaxel (Primary) ; Prednisolone (Primary) ; Prednisone (Primary) ; Granulocyte colony-stimulating factors
- Indications Carcinoma; Prostate cancer
- Focus Adverse reactions
- Acronyms CABASTY
- 24 Oct 2023 Results of Pain response and health-related quality of life , presented at the 48th European Society for Medical Oncology Congress
- 18 Feb 2023 Primary endpoint (Number of grade 3 neutropenia and/or neutropenic complications) has been met, according to results presented at the 2023 Genitourinary Cancers Symposium.
- 18 Feb 2023 Results assessing the prognostic impact of neutrophil-to-lymphocyte ratio (NLR), neutrophil-to-platelets ratio (NPR) myeloid derived suppressor cells (MDSC) and leukocyte subtypes counts , presented at the 2023 Genitourinary Cancers Symposium.